<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>UROCIT-K - potassium citrate tablet, extended release </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Urocit<span class="Sup">®</span>-K safely and effectively. See full prescribing information for Urocit<span class="Sup">®</span>-K. <br> <br>Urocit<span class="Sup">®</span>-K (Potassium Citrate) Extended-release tablets for oral use <br>Initial U.S. Approval: 1985</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="idb838417-3c5d-40d3-853d-4c089e377c1e"></a><table width="75%">
<col align="left" valign="top" width="60%">
<col align="right" valign="top" width="40%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Dosage and Administration, Urocit<span class="Sup">®</span>-K 15 mEq (<a href="#S2.2">2.2</a>, <a href="#S2.3">2.3</a>)</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td align="left">Dosage Forms and Strengths, Urocit<span class="Sup">®</span>-K 15 mEq (<a href="#S3">3</a>)</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td align="left">Description, Urocit<span class="Sup">®</span>-K 15 mEq (<a href="#S11">11</a>)</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td align="left">Clinical Studies (<a href="#S14">14</a>)</td>
<td align="right">12/2009</td>
</tr>
<tr class="Botrule Last">
<td align="left">How Supplied/Storage and Handling, Urocit<span class="Sup">®</span>-K 15 mEq (<a href="#S16">16</a>)</td>
<td align="right">12/2009</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Urocit<span class="Sup">®</span>-K is a citrate salt of potassium indicated for the management of: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal tubular acidosis</span> (RTA) with calcium stones (<a href="#S1.1">1.1</a>)</li>
<li>Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> of any etiology (<a href="#S1.2">1.2</a>)</li>
<li>Uric acid lithiasis with or without calcium stones (<a href="#S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. </p>
<ul>
<li>Severe hypocitraturia (urinary citrate &lt; 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (<a href="#S2.2">2.2</a>)</li>
<li>Mild to moderate hypocitraturia (urinary citrate &gt;150 mg/day): therapy should be initi-ated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times -per day with meals or within 30 minutes after meals or bedtime snack (<a href="#S2.3">2.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 5 mEq, 10 mEq and 15 mEq (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (or who have conditions predisposing them to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>). Such conditions include <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, strenuous physical exercise in unconditioned individuals, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, extensive tissue breakdown (<a href="#S4">4</a>)</li>
<li>Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span>, esophageal compression, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> or stricture (<a href="#S4">4</a>)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> (<a href="#S4">4</a>)</li>
<li>Patients with active <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (<a href="#S4">4</a>)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (glomerular filtration rate of less than 0.7 ml/kg/min) (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>: In patients with impaired mechanisms for excreting potassium, Urocit<span class="Sup">®</span>-K administration can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop rapidly and be asymptomatic. The use of Urocit<span class="Sup">®</span>-K in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, or any other condition which impairs potassium excretion such as severe myocardial damage or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, should be avoided (<a href="#S5.1">5.1</a>)</li>
<li>Gastrointestinal lesions: if there is severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, Urocit<span class="Sup">®</span>-K should be discontinued immediately and the possibility of <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span> or obstruction investigated (<a href="#S5.2">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Some patients may develop minor gastrointestinal complaints such as <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose bowel</span> movements or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. These may be alleviated by taking the dose with meals or snacks or by reducing the dosage (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or</span><span class="Bold Italics"> www.fda.gov/medwatch</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">The following drug interactions may occur with potassium citrate: </p>
<ul>
<li>Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#S7.1">7.1</a>)</li>
<li>Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> produced by potassium salts (<a href="#S7.2">7.2</a>)</li>
</ul>
</div>
<div><div></div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnant women: Pregnancy Category C; animal reproduction studies have not been conducted. It is not known whether Urocit<span class="Sup">®</span>-K can cause fetal harm when administered -to a pregnant woman or can affect reproduction capacity. Urocit<span class="Sup">®</span>-K should be given to a pregnant woman only if clearly needed (<a href="#S8.1">8.1</a>)</li>
<li>Nursing mothers: The normal potassium ion content of human milk is about 13 mEq/L. It is not known if Urocit<span class="Sup">®</span>-K has an effect on this content. Urocit<span class="Sup">®</span>-K should be given to a woman who is breast feeding only if clearly needed (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric Use: Safety and effectiveness in children have not been established (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal tubular acidosis</span> (RTA) with calcium stones</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> of any etiology</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Uric acid lithiasis with or without calcium stones</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Severe Hypocitraturia</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Mild to Moderate Hypocitraturia</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Gastrointestinal Lesions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential Effects of Potassium citrate on Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential Effects of Other Drugs on Potassium citrate</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal tubular acidosis</span> (RTA) with calcium stones</a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> of any etiology</a></h2>
<h2><a href="#section-12.3" class="toc">14.3 Uric acid lithiasis with or without calcium stones</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Administration of Drug</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal tubular acidosis</span> (RTA) with calcium stones</h2>
<p class="First">Potassium citrate is indicated for the management of <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span> <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> of any etiology</h2>
<p class="First">Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Uric acid lithiasis with or without calcium stones</h2>
<p class="First">Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see <a href="#S14.3">Clinical Studies (14.3)</a><span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Instructions</h2>
<p class="First">Treatment with extended release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least two liters per day). The objective of treatment with Urocit<span class="Sup">®</span>-K is to provide Urocit<span class="Sup">®</span>-K in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0.</p>
<p>Monitor serum electrolytes (sodium, potassium, chloride and <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>), serum creatinine and complete blood counts every four months and more frequently in patients with cardiac disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Perform electrocardiograms periodically. Treatment should be discontinued if there is <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, a significant rise in serum creatinine or a significant <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in blood hemocrit or hemoglobin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Severe Hypocitraturia</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In patients with severe hypocitraturia (urinary citrate &lt; 150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (30 mEq two times/day or 20 mEq three times/day with meals or within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. In addition, urinary citrate and/or pH should be measured every four months. Doses of Urocit<span class="Sup">®</span>-K greater than 100 mEq/day have not been studied and should be avoided.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Mild to Moderate Hypocitraturia</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In patients with mild to moderate hypocitraturia (urinary citrate &gt; 150 mg/day) therapy should be initiated at 30 mEq/day (15 mEq two times/day or 10 mEq three times/day within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. Doses of Urocit<span class="Sup">®</span>-K greater than 100 mEq/day have not been studied and should be avoided.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li style="border-left:1px solid;"><span class="XmChange">5 mEq tablets are uncoated, tan to yellowish in color, modified ball shaped, with MPC 600 debossed on one side and blank on the other</span></li>
<li>10 mEq tablets are uncoated, tan to yellowish in color, elliptical shaped, with 610 debossed on one side and MISSION on the other</li>
<li>15 mEq tablets are uncoated, tan to yellowish in color, modified rectangle shaped, with M15 debossed on one side and blank on the other</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Urocit<span class="Sup">®</span>-K is contraindicated:</p>
<ul>
<li>In patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (or who have conditions pre-disposing them to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>), as a further rise in serum potassium concentration may produce <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Such conditions include: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, strenuous physical exercise in unconditioned individuals, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride).</li>
<li>In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span>, esophageal compression, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> or stricture, or those taking anticholinergic medication.</li>
<li>In patients with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> because of its ulcerogenic potential.</li>
<li>In patients with active <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Urocit<span class="Sup">®</span>-K to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from Urocit<span class="Sup">®</span>-K therapy might promote further bacterial growth.</li>
<li>In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">In patients with impaired mechanisms for excreting potassium, Urocit<span class="Sup">®</span>-K administration can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop rapidly and be asymptomatic. The use of Urocit<span class="Sup">®</span>-K in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, or any other condition which impairs potassium excretion such as severe myocardial damage or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, should be avoided. Closely monitor for signs of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with periodic blood tests and ECGs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Gastrointestinal Lesions</h2>
<p class="First">Because of reports of upper gastrointestinal mucosal lesions following administration of potassium chloride (wax-matrix), an endoscopic examination of the upper gastrointestinal mucosa was performed in 30 normal volunteers after they had taken glycopyrrolate 2 mg p.o. t.i.d., Urocit<span class="Sup">®</span>-K 95 mEq/day, wax-matrix potassium chloride 96 mEq/day or wax-matrix placebo, in thrice daily schedule in the fasting state for one week. Urocit<span class="Sup">®</span>-K and the wax-matrix formulation of potassium chloride were indistinguishable but both were significantly more irritating than the wax-matrix placebo. In a subsequent, similar study, lesions were less severe when glycopyrrolate was omitted.</p>
<p>Solid dosage forms of potassium chlorides have produced stenotic and/or ulcerative lesions of the small bowel and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. These lesions are caused by a high local concentration of potassium ions in the region of the dissolving tablets, which injured the bowel. In addition, perhaps because wax-matrix preparations are not enteric-coated and release some of their potassium content in the stomach, there have been reports of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> associated with these products. The frequency of gastrointestinal lesions with wax-matrix potassium chloride products is estimated at one per 100,000 patient-years. Experience with Urocit<span class="Sup">®</span>-K is limited, but a similar frequency of gastrointestinal lesions should be anticipated.</p>
<p>If there is severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, Urocit<span class="Sup">®</span>-K should be discontinued immediately and the possibility of <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span> or obstruction investigated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Postmarketing Experience</h2>
<p class="First">Some patients may develop minor gastrointestinal complaints during Urocit<span class="Sup">®</span>-K therapy, such as <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose bowel</span> movements or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. These symptoms are due to the irritation of the gastrointestinal tract, and may be alleviated by taking the dose with meals or snacks, or by reducing the dosage. Patients may find intact matrices in their feces.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential Effects of Potassium citrate on Other Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics">Potassium-sparing Diuretics:</span> Concomitant administration of Urocit<span class="Sup">®</span>-K and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential Effects of Other Drugs on Potassium citrate</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Italics">Drugs that slow gastrointestinal transit time:</span> These agents (such as anticholinergics) can be expected to increase the <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> produced by potassium salts.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been conducted. It is also not known whether Urocit<span class="Sup">®</span>-K can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Urocit<span class="Sup">®</span>-K should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The normal potassium ion content of human milk is about 13 mEq/L. It is not known if Urocit<span class="Sup">®</span>-K has an effect on this content. Urocit<span class="Sup">®</span>-K should be given to a woman who is breast feeding only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Italics">Treatment of Overdosage:</span> The administration of potassium salts to persons without predisposing conditions for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> rarely causes serious <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> at recommended dosages. It is important to recognize that <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-wave, loss of P-wave, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of S-T segment and prolongation of the QT interval). Late manifestations include muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>Treatment measures for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include the following:</p>
<ol>
<li>Patients should be closely monitored for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and electrolyte changes.</li>
<li>Elimination of medications containing potassium and of agents with potassium-sparing properties such as potassium-sparing diuretics, ARBs, ACE inhibitors, NSAIDs, certain nutritional supplements and many others.</li>
<li>Elimination of foods containing high levels of potassium such as almonds, apricots, bananas, beans (lima, pinto, white), cantaloupe, carrot juice (canned), figs, grapefruit juice, halibut, milk, oat bran, potato (with skin), salmon, spinach, tuna and many others.</li>
<li>Intravenous calcium gluconate if the patient is at no risk or low risk of developing <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</li>
<li>Intravenous administration of 300-500 mL/hr of 10% dextrose solution containing 10-20 units of crystalline insulin per 1,000 mL.</li>
<li>Correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, if present, with intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</li>
<li>Hemodialysis or peritoneal dialysis.</li>
<li>Exchange resins may be used. However, this measure alone is not sufficient for the acute treatment of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</li>
</ol>
<p>Lowering potassium levels too rapidly in patients taking digitalis can produce <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Urocit<span class="Sup">®</span>-K is a citrate salt of potassium. Its empirical formula is K<span class="Sub">3</span>C<span class="Sub">6</span>H<span class="Sub">5</span>O<span class="Sub">7</span> • H<span class="Sub">2</span>O, and it has the following chemical structure:</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2c923d5-85c1-4bbb-9f93-556080a5ef87&amp;name=urocit-k-01.jpg"></div>
<p>Urocit<span class="Sup">®</span>-K yellowish to tan, oral wax-matrix tablets, contain 5 mEq (540 mg) potassium citrate, 10 mEq (1080 mg) potassium citrate and 15 mEq (1620 mg) potassium citrate each. Inactive ingredients include carnauba wax and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">When Urocit<span class="Sup">®</span>-K is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, Urocit<span class="Sup">®</span>-K therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, citrate had a greater effect on urinary citrate.</p>
<p>In addition to raising urinary pH and citrate, Urocit<span class="Sup">®</span>-K increases urinary potassium by approximately the amount contained in the medication. In some patients, Urocit<span class="Sup">®</span>-K causes a transient reduction in urinary calcium.</p>
<p>The changes induced by Urocit<span class="Sup">®</span>-K produce urine that is less conducive to the crystallization of stone-forming salts (calcium oxalate, calcium phosphate and uric acid). Increased citrate in the urine, by complexing with calcium, decreases calcium ion activity and thus the saturation of calcium oxalate. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate (brushite).</p>
<p>The increase in urinary pH also decreases calcium ion activity by increasing calcium complexation to dissociated anions. The rise in urinary pH also increases the ionization of uric acid to the more soluble urate ion.</p>
<p>Urocit<span class="Sup">®</span>-K therapy does not alter the urinary saturation of calcium phosphate, since the effect of increased citrate complexation of calcium is opposed by the rise in pH-dependent dissociation of phosphate. Calcium phosphate stones are more stable in alkaline urine.</p>
<p>In the setting of normal renal function, the rise in urinary citrate following a single dose begins by the first hour and lasts for 12 hours. With multiple doses the rise in citrate excretion reaches its peak by the third day and averts the normally wide circadian fluctuation in urinary citrate, thus maintaining urinary citrate at a higher, more constant level throughout the day. When the treatment is withdrawn, urinary citrate begins to decline toward the pre-treatment level on the first day.</p>
<p>The rise in citrate excretion is directly dependent on the Urocit<span class="Sup">®</span>-K dosage. Following long-term treatment, Urocit<span class="Sup">®</span>-K at a dosage of 60 mEq/day raises urinary citrate by approximately 400 mg/day and increases urinary pH by approximately 0.7 units.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span> or chronic diarrheal syndrome where urinary citrate may be very low (&lt;100 mg/day), Urocit<span class="Sup">®</span>-K may be relatively ineffective in raising urinary citrate. A higher dose of Urocit<span class="Sup">®</span>-K may therefore be required to produce a satisfactory citraturic response. In patients with <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span> in whom urinary pH may be high, Urocit<span class="Sup">®</span>-K produces a relatively small rise in urinary pH.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The pivotal Urocit<span class="Sup">®</span>-K trials were non-randomized and non-placebo controlled where dietary management may have changed coincidentally with pharmacological treatment. Therefore, the results as presented in the following sections may overstate the effectiveness of the product.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal tubular acidosis</span> (RTA) with calcium stones</h2>
<p class="First">The effect of oral potassium citrate therapy in a non-randomized, non-placebo controlled clinical study of five men and four women with calcium oxalate/calcium phosphate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> and documented incomplete distal <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span> was examined. The main inclusion criterion was a history of stone passage or surgical removal of stones during the 3 years prior to initiation of potassium citrate therapy. All patients began alkali treatment with 60-80 mEq potassium citrate daily in 3 or 4 divided doses. Throughout treatment, patients were instructed to stay on a sodium restricted diet (100 mEq/day) and to reduce oxalate intake (limited intake of nuts, dark roughage, chocolate and tea). A moderate calcium restriction (400-800 mg/day) was imposed on patients with <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>.</p>
<p>X-rays of the urinary tract, available in all patients, were reviewed to determine presence of pre-existing stones, appearance of new stones, or change in the number of stones.</p>
<p>Potassium citrate therapy was associated with inhibition of new stone formation in patients with distal tubular <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Three of the nine patients continued to pass stones during the on-treatment phase. While it is likely that these patients passed pre-existing stones during therapy, the most conservative assumption is that the passed stones were newly formed. Using this assumption, the stone-passage remission rate was 67%. All patients had a reduced stone formation rate. Over the first 2 years of treatment, the on-treatment stone formation rate was reduced from 13±27 to 1±2 per year.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Hypocitraturic calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> of any etiology</h2>
<p class="First">Eighty-nine patients with hypocitraturic calcium <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> or uric acid lithiasis with or without calcium <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> participated in this non-randomized, non-placebo controlled clinical study. Four groups of patients were treated with potassium citrate: Group 1 was comprised of 19 patients, 10 with <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span> and 9 with chronic diarrheal syndrome, Group 2 was comprised of 37 patients, 5 with uric acid stones alone, 6 with uric acid lithiasis and calcium stones, 3 with type 1 absorptive <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, 9 with type 2 absorptive <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> and 14 with hypocitraturia. Group 3 was comprised of 15 patients with history of relapse on other therapy and Group 4 was comprised of 18 patients, 9 with type 1 absorptive <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> and calcium stones, 1 with type 2 absorptive <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> and calcium stones, 2 with hyperuricosuric calcium oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, 4 with uric acid lithiasis accompanied by calcium stones and 2 with hypocitraturia and <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> accompanied by calcium stones. The dose of potassium citrate ranged from 30 to 100 mEq per day, and usually was 20 mEq administered orally 3 times daily. Patients were followed in an outpatient setting every 4 months during treatment and were studied over a period from 1 to 4.33 years. A three-year retrospective pre-study history for stone passage or removal was obtained and corroborated by medical records. Concomitant therapy (with thiazide or allopurinol) was allowed if patients had <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, <span class="product-label-link" type="condition" conceptid="4057743" conceptname="Hyperuricuria">hyperuricosuria</span> or <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>. Group 2 was treated with potassium citrate alone.</p>
<p>In all groups, treatment that included potassium citrate was associated with a sustained increase in urinary citrate excretion from subnormal values to normal values (400 to 700 mg/day), and a sustained increase in urinary pH from 5.6-6.0 to approximately 6.5. The stone formation rate was reduced in all groups as shown in<span class="Bold"> Table 1</span>.</p>
<a name="i9ac1280d-46f4-4b68-8d04-f7c137dce20c"></a><table width="75%">
<caption><span>Table 1. Effect of Urocit<span class="Sup">®</span>-K In Patients With Calcium Oxalate <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span>.</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="5">Stones Formed Per Year</th></tr>
<tr class="Last">
<th class="Lrule" align="center">Group</th>
<th class="Lrule" align="center">Baseline</th>
<th class="Lrule" align="center">On Treatment</th>
<th class="Lrule" align="center">Remission<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center">Any Decrease</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Remission defined as "the percentage of patients remaining free of newly formed stones during treatment".</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">I (n=19)</td>
<td class="Lrule" align="center">12 ± 30</td>
<td class="Lrule" align="center">0.9 ± 1.3</td>
<td class="Lrule" align="center">58%</td>
<td class="Lrule Rrule" align="center">95%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">II (n=37)</td>
<td class="Lrule" align="center">1.2 ± 2</td>
<td class="Lrule" align="center">0.4 ± 1.5</td>
<td class="Lrule" align="center">89%</td>
<td class="Lrule Rrule" align="center">97%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">III (n=15)</td>
<td class="Lrule" align="center">4.2 ± 7</td>
<td class="Lrule" align="center">0.7 ± 2</td>
<td class="Lrule" align="center">67%</td>
<td class="Lrule Rrule" align="center">100%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">IV (n=18)</td>
<td class="Lrule" align="center">3.4 ± 8</td>
<td class="Lrule" align="center">0.5 ± 2</td>
<td class="Lrule" align="center">94%</td>
<td class="Lrule Rrule" align="center">100%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">Total (n=89)</td>
<td class="Lrule" align="center">4.3 ±15</td>
<td class="Lrule" align="center">0.6 ± 2</td>
<td class="Lrule" align="center">80%</td>
<td class="Lrule Rrule" align="center">98%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-12.3"></a><p></p>
<h2>14.3 Uric acid lithiasis with or without calcium stones</h2>
<p class="First">A long-term non-randomized, non-placebo controlled clinical trial with eighteen adult patients with uric acid lithiasis participated in the study. Six patients formed only uric acid stones, and the remaining 12 patients formed mixed stones containing both uric acid and calcium salts or formed both uric acid stones (without calcium salts) and calcium stones (without uric acid) on separate occasions.</p>
<p>Eleven of the 18 patients received potassium citrate alone. Six of the 7 other patients also received allopurinol for <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> with <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, symptomatic <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, or <span class="product-label-link" type="condition" conceptid="4057743" conceptname="Hyperuricuria">hyperuricosuria</span>. One patient also received hydrochlorothiazide because of unclassified <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>. The main inclusion criterion was a history of stone passage or surgical removal of stones during the 3 years prior to initiation of potassium citrate therapy. All patients received potassium citrate at a dosage of 30-80 mEq/day in three-to-four divided doses and were followed every four months for up to 5 years.</p>
<p>While on potassium citrate treatment, urinary pH rose significantly from a low value of 5.3 ± 0.3 to within normal limits (6.2 to 6.5). Urinary citrate which was low before treatment rose to the high normal range and only one stone was formed in the entire group of 18 patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Pak, C. (1987). Citrate and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal Calculi</span>. <span class="Italics">Mineral and Electrolyte Metabolism</span> 13, 257-266.</li>
<li>Pak, C. (1985). Long-Term Treatment of Calcium <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span> with Potassium Citrate. <span class="Italics">The Journal of Urology</span> 134, 11-19.</li>
<li>Preminger, G.M., K. Sakhaee, C. Skurla and C.Y.C. Pak. (1985). Prevention of Recurrent Calcium Stone Formation with Potassium Citrate Therapy in Patients with Distal <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">Renal Tubular Acidosis</span>. <span class="Italics">The Journal of Urology</span> 134, 20-23.</li>
<li>Pak, C.Y.C., K. Sakhaee and C. Fuller. (1986). Successful Management of Uric Acid <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span> with Potassium Citrate. <span class="Italics">Kidney International</span> 30, 422-428.</li>
<li>Hollander-Rodriguez, J et al. (2006). <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="Italics">American Family Physician</span>, Vol. 73/No. 2.</li>
<li>Greenberg, A et al. (1998). <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>: treatment options. <span class="Italics">Semen Nephrol.</span> Jan; 18 (1): 46-57.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<br><p class="First">Urocit<span class="Sup">®</span>-K 10 mEq tablets are uncoated, tan to yellowish in color, elliptical shaped, with MPC 610 debossed on one side and MISSION on the other, supplied in bottles as:</p>
<a name="iae9328b8-fd65-45d1-84e3-a04b095adeea"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 20<br>
</td>
<td>NDC 54868-4779-1<br>
</td>
</tr>
<tr>
<td>Bottles of 60<br>
</td>
<td>NDC 54868-4779-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-4779-2<br>
</td>
</tr>
</tbody></table>
<p>Urocit<span class="Sup">®</span>-K 15 mEq tablets are uncoated, tan to yellowish in color, modified rectangle shaped, with M15 debossed on one side and blank on the other, supplied in bottles as:</p>
<a name="i477ba80c-d1a1-498d-80fd-8a704f43ec51"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-6176-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 60<br>
</td>
<td>NDC 54868-6176-1<br>
</td>
</tr>
</tbody></table>
<br><div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Italics">Storage:</span> Store in a tight container.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Administration of Drug</h2>
<p class="First">Tell patients to take each dose without crushing, chewing or sucking the tablet.</p>
<p>Tell patients to take this medicine only as directed. This is especially important if the patient is also taking both diuretics and digitalis preparations.</p>
<p>Tell patients to check with the doctor if there is trouble swallowing tablets or if the tablet seems to stick in the throat.</p>
<p>Tell patients to check with the doctor at once if <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span> or other evidence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> is noticed.</p>
<p>Tell patients that their doctor will perform regular blood tests and electrocardiograms to ensure safety.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First">KP-503 C01 Rev 012090</p>
<p>MISSION PHARMACAL COMPANY, SAN ANTONIO, TX USA 78230 1355</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK        74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mEq Bottle Label</span></p>
<p><span class="Bold"></span><br></p>
<p><span class="Bold">UROCIT<span class="Sup">®</span>-K</span></p>
<p><span class="Bold">10 mEq</span></p>
<p><span class="Bold">(Potassium Citrate)</span><br>Extended-release tablet</p>
<p>10 mEq (1080 mg) per tablet</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="image of 10 mEq package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2c923d5-85c1-4bbb-9f93-556080a5ef87&amp;name=4779.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 mEq Bottle Label</span></p>
<p><span class="Bold"></span><br></p>
<p><span class="Bold">UROCIT<span class="Sup">®</span>-K</span></p>
<p><span class="Bold">15 mEq</span></p>
<p><span class="Bold">(Potassium Citrate)</span><br>Extended-release tablet</p>
<p>15 mEq (1620 mg) per tablet</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="image of 15 mEq package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2c923d5-85c1-4bbb-9f93-556080a5ef87&amp;name=6176.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UROCIT-K 		
					</strong><br><span class="contentTableReg">potassium citrate tablet, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4779(NDC:0178-0610)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CITRATE</strong> (POTASSIUM CATION) </td>
<td class="formItem">POTASSIUM CITRATE</td>
<td class="formItem">10 meq</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (tan to yellowish) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ellipitcal) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MPC;610;MISSION</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4779-0</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4779-1</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4779-2</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019071</td>
<td class="formItem">04/17/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UROCIT-K 		
					</strong><br><span class="contentTableReg">potassium citrate tablet, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6176(NDC:0178-0615)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CITRATE</strong> (POTASSIUM CATION) </td>
<td class="formItem">POTASSIUM CITRATE</td>
<td class="formItem">15 meq</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (tan to yellowish) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">RECTANGLE (modified rectangle) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6176-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6176-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019071</td>
<td class="formItem">09/15/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>09893986-19e0-4364-93ba-5fbc7e7d3eed</div>
<div>Set id: d2c923d5-85c1-4bbb-9f93-556080a5ef87</div>
<div>Version: 1</div>
<div>Effective Time: 20100423</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
